TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.

by Gary J Haderski, Bojidar M Kandar, Craig M Brackett, Ilia M Toshkov, Christopher P Johnson, Geraldine M Paszkiewicz, Venkatesh Natarajan, Anatoli S Gleiberman, Andrei V Gudkov, Lyudmila G Burdelya
Published 2020-01-01

Signaling through TLR5 mitigates lethal radiation damage by neutrophil-dependent release of MMP-9

by Craig M. Brackett, Kellee F. Greene, Alyssa R. Aldrich, Nicholas H. Trageser, Srabani Pal, Ivan Molodtsov, Bojidar M. Kandar, Lyudmila G. Burdelya, Scott I. Abrams, Andrei V. Gudkov
Published 2021-09-01